Hans van Houte serves as the Chief Financial Officer (CFO) at Nurix Therapeutics Inc., a biopharmaceutical company focused on developing novel therapies for cancer and other challenging diseases. In his role as CFO, van Houte is responsible for overseeing the financial strategy and operations of the company, ensuring its fiscal health and supporting its growth trajectory. His leadership has been instrumental in guiding Nurix through various stages of its development, from early-stage research to clinical trials and beyond. Van Houte brings a wealth of experience to Nurix, having held significant financial leadership positions in the biotechnology and pharmaceutical industries. Prior to joining Nurix, he served as CFO at other notable biotech firms, where he successfully managed financings, mergers and acquisitions, and strategic partnerships. His expertise in financial planning and analysis, coupled with a deep understanding of the biotech sector, has enabled him to effectively navigate the complex financial landscape of drug development. Van Houte's strategic financial management has been crucial in securing the resources needed to advance Nurix's innovative pipeline of therapeutics. In addition to his professional achievements, van Houte is recognized for his contributions to the broader biotech community. He is often invited to speak at industry conferences and participates in panels discussing financial strategies for emerging biotech companies. His commitment to fostering innovation and growth within the sector underscores his role not only as a financial leader at Nurix but also as a thought leader in the biotechnology field. Under his financial stewardship, Nurix continues to make significant strides towards bringing new treatment options to patients in need.